Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients with Metastatic Platinum-Resistant Urothelial Carcinoma

Clinical Genitourinary Cancer

Volumn 14, Issue 1, 2016, Pages e75-e79

  Faltas, Bishoy ^a   Goldenberg, David M ^b   Ocean, Allyson J ^a   Govindan, Serengulam V ^b   Wilhelm, Francois ^b   Sharkey, Robert M ^b   Hajdenberg, Julio ^c   Hodes, Gillian ^a   Nanus, David M ^a   Tagawa, Scott T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IMMUNOMEDICS INC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antibody drug conjugates; Clinical trial; IMMU 132; Sacituzumab govitecan; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; FIRTECAN; GEMCITABINE; ICRUCUMAB; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; SACITUZUMAB GOVITECAN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG CONJUGATION; FEMALE; FLANK PAIN; HUMAN; MALE; MIDDLE AGED; OVERALL SURVIVAL; PLATINUM RESISTANT UROTHELIAL CARCINOMA; PROGRESSION FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; LYMPHATIC METASTASIS; MALE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84951801438     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.10.002     Document Type: Article

References (20)

1. United States Cancer Statistics. Available at: http://nccd.cdc.gov/USCS/toptencancers.aspx. Accessed October 29, 2015.
2. American Cancer Society bladder cancer statistics. Available at: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed October 29, 2015.
3. C. Logothetis, F.H. Dexeus, L. Finn, and et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
4. P.J. Loehrer Sr., L.H. Einhorn, P.J. Elson, and et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
5. H. von der Maase, L. Sengelov, J.T. Roberts, and et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
6. J. Bellmunt, C. Théodore, T. Demkov, and et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
7. B.M. Faltas, B.S. Karir, S.T. Tagawa, and J.E. Rosenberg Novel molecular targets for urothelial carcinoma Expert Opin Ther Targets 19 2015 515 525
8. T.M. Cardillo, S.V. Govindan, R.M. Sharkey, and et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers Bioconjug Chem 26 2015 919 931
9. D.M. Goldenberg, T.M. Cardillo, S.V. Govindan, E.A. Rossi, and R.M. Sharkey Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) Oncotarget 6 2015 22496 22512
10. A.N. Starodub, A.J. Ocean, M.A. Shah, and et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors Clin Cancer Res 21 2015 3870 3878
11. L.P. Stepan, E.S. Trueblood, K. Hale, J. Babcock, L. Borges, and C.L. Sutherland Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target J Histochem Cytochem 59 2011 701 710
12. TACSTD2: gene information. The Human Protein Atlas. Available at: http://www.proteinatlas.org/ENSG00000184292-TACSTD2/gene. Accessed October 29, 2015.
13. T.M. Beer, B. Goldman, C.R. Nichols, and et al. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy Clin Genitourin Cancer 6 2008 36 39
14. U.B. Chaudhary, N. Verma, T. Keane, and V. Gudena A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer Am J Clin Oncol 37 2014 188 193
15. G. Sonpavde, G.R. Pond, J.E. Rosenberg, and et al. Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma J Clin Oncol 33 suppl 7 2015 abstract 311
16. C.J. Sweeney, B.J. Roth, F.F. Kabbinavar, and et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451 3457
17. M.D. Galsky, S. Mironov, A. Iasonos, J. Scattergood, M.G. Boyle, and D.F. Bajorin Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Invest New Drugs 25 2007 265 270
18. D.P. Petrylak, K.N. Chi, N.J. Vogelzang, and et al. Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy J Clin Oncol 30 2012 abstract TPS4675
19. R.M. Bambury, D.J. Benjamin, J.L. Chaim, and et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Oncologist 20 2015 508 515
20. R.M. Sharkey, W.J. McBride, T.M. Cardillo, and et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan) Clin Cancer Res 21 2015 3870 3878